« Return to News | Drug Sponsors

Bayer will consolidate in New Jersey

Tuesday, April 5, 2011 02:41 PM

Bayer HealthCare has selected New Jersey as the place to consolidate its East-Coast business site.

"We are very excited about the prospect of having a new site and facility that can house East Coast-based Bayer HealthCare employees from every division and function under one roof," said Mark Trudeau, president and CEO, Bayer HealthCare Pharmaceuticals and chair of the company's U.S. East Coast Site Search Committee. "New Jersey is home to many biopharmaceutical and healthcare companies, and we look forward to benefiting from the many resources and opportunities available to us in the state."

Commenting on the company's decision, Governor Chris Christie said, "Bayer's commitment to stay and expand in New Jersey is another signal that our state is growing and that this administration's job creating policies are paying dividends. Bayer's planned investment in New Jersey will help keep us the premier state in the nation for the pharmaceutical industry in addition to creating needed jobs and giving a boost to our state's economy."

Although a specific location has not yet been chosen, several sites near the company's existing New Jersey locations are under consideration. Between its divisions and corporate functions the company employs approximately 2,500 people in the New Jersey and New York area.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.